專家問答：生成式人工智慧如何讓 GVD 製作更簡單

隨著越來越多的製藥公司考慮使用生成式人工智慧來增強全球價值檔案 (GVD) 的創建，簡化工作流程、整合證據和優化上市策略的潛力正變得越來越明顯。

為了了解人工智慧如何改變這個過程，FirstWord 採訪了 S3 Connected Health 的諮詢服務專案經理 Hany Mina。

報告的內容

• 生成式 AI 目前如何用於建立 GVD？
• 與傳統方法相比，生成式 AI 為 GVD 創作過程帶來了哪些獨特優勢？
• 生成式 AI 將如何改變從事 GVD 的醫學寫作和市場進入團隊的工作流程？
• 生成式 AI 在為 GVD 創建核心內容（例如價值敘述、臨床摘要和經濟模型資料）方面有多有效？
• 生成式 AI 能否協助針對特定市場或受眾客製化 GVD？
• 在 GVD 開發中使用生成式 AI 時，您節省了哪些時間和成本？
• 確保資料準確性在 GVD 中非常重要，但需要採取哪些措施來驗證生成式 AI 的輸出？
• 如何使用生成式人工智慧為不同的利害關係人客製化 GVD 的內容？
• 我們如何控制生成式 AI 的資料輸入，以便僅連接已識別的資料來源並使用正確的資料來支援 GVD 的生成？
• 如何優化生成式人工智慧以滿足 GVD 嚴格的監管標準，尤其是在受到嚴格監管的市場中？
• 生成式人工智慧的創新預計將在未來五年對 GVD 創作產生最大影響
• 考慮到生成式 AI 在創建 GVD 方面的整體情況，您是否建議添加其他模組或解決方案？
• 對於剛開始考慮使用生成式 AI 進行 GVD 開發的公司，您會給予什麼建議？

As pharmas increasingly explore genAI to enhance global value dossier (GVD) creation, its potential to streamline workflows, synthesise evidence and optimise market access strategies is becoming more apparent.

To understand how AI is transforming this process, FirstWord spoke with Hany Mina, consulting services program manager at S3 Connected Health.

Key Questions Answered:

• How is genAI currently being used in GVD creation?
• What unique advantages does genAI bring to the process of creating GVDs compared with traditional approaches?
• Do you see genAI transforming workflows within the medical writing and market access teams responsible for GVDs?
• How effective is genAI in generating core GVD content, such as value narratives, clinical summaries and economic modelling data?
• Can genAI assist in tailoring GVDs for specific markets or audiences?
• What kind of time and cost-savings have you observed when using genAI for GVD development?
• Ensuring data accuracy is critical in a GVD. What measures are necessary to validate outputs from genAI?
• How can genAI be leveraged to tailor GVD content for different stakeholders?
• How can we control the data input to genAI to ensure only identified data sources are connected and correct data are consumed to support GVD generation?
• How can genAI be optimised to meet stringent regulatory standards in GVDs, especially in highly regulated markets?
• What innovations in genAI do you foresee having the biggest impact on GVD creation in the next five years?
• Thinking of the big picture for genAI in GVD creation, are there other modules or solutions you suggest adding?
• What advice would you give to companies just beginning to explore genAI for GVD development?

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.